Search

Displaying results 4321 - 4330 of 5758 in total
  1. Drug

    Prolgolimab

    go.drugbank.com/drugs/DB16740
    Investigational

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
  2. Drug

    Eliapixant

    go.drugbank.com/drugs/DB21465
    Investigational

    Eliapixant has a monoisotopic molecular weight of 478.13 Da.

  3. Drug

    Insulin degludec

    go.drugbank.com/drugs/DB09564
    ApprovedInvestigational

    prescribed later in the course of T2D, after several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic cells that the body is no

    Mixtures: Ryzodeg® FlexTouch® 100 U/ml Solution for Injection, RYZODEG PENFİLL 100 U/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KARTUŞ, 5 ADETCategories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 Enzyme Inducers
  4. Drug

    Velpatasvir

    go.drugbank.com/drugs/DB11613
    ApprovedInvestigational

    Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  5. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavabl...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    JNJ-55308942

    go.drugbank.com/drugs/DB19110
    Investigational

    JNJ-55308942 is under investigation in clinical trial NCT05328297 (A Study of JNJ-55308942 in the Treatment of Bipolar Depression).

    Categories: Purinergic P2 Receptor Antagonists
  7. Drug

    LJ-2698

    go.drugbank.com/drugs/DB18018
    Experimental

    Categories: Purinergic P1 Receptor Antagonists
  8. Drug

    Vipadenant

    go.drugbank.com/drugs/DB06625
    Investigational

    Categories: Purinergic P1 Receptor Antagonists
  9. Drug

    Naxifylline

    go.drugbank.com/drugs/DB06471
    Experimental

    Categories: Purinergic P1 Receptor Antagonists
  10. Drug

    Ledipasvir

    go.drugbank.com/drugs/DB09027
    Approved

    Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates